Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 9/2018

01-09-2018 | Letter to the Editor

Successful full-dose DeVIC therapy in a patient with advanced-stage extranodal natural killer/T-cell lymphoma refractory to l-asparaginase

Authors: Junko Watanabe, Shinichi Makita, Yuta Ito, Shunsuke Hatta, Tomotaka Suzuki, Sayako Yuda, Akiko Miyagi Maeshima, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Dai Maruyama, Sung-Won Kim, Koji Izutsu

Published in: Annals of Hematology | Issue 9/2018

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Makita S, Tobinai K (2017) Clinical features and current optimal management of natural killer/T-cell lymphoma. Hematol Oncol Clin North Am 31:239–253CrossRefPubMed
2.
Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Ohshima K, Matsuno Y, Terauchi T, Nawano S, Ishikura S, Kagami Y, Hotta T, Oshimi K (2009) Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 27:5594–5600CrossRefPubMed
3.
Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R (2011) Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 29:4410–4416CrossRefPubMed
4.
Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, Shirakawa S, Fukumoto M (1995) Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 76:2351–2356CrossRefPubMed
5.
Ando M, Sugimoto K, Kitoh T, Sasaki M, Mukai K, Ando J, Egashira M, Schuster SM, Oshimi K (2005) Selective apoptosis of natural killer-cell tumours by L-asparaginase. Br J Haematol 130:860–868CrossRefPubMed
6.
Kwong YL, Anderson BO, Advani R, Kim WS, Levine AM, Lim ST, Asian Oncology Summit (2009) Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10:1093–1101CrossRefPubMed
7.
Lim SH, Hong JY, Lim ST, Hong H, Arnoud J, Zhao W, Yoon DH, Tang T, Cho J, Park S, Ko YH, Kim SJ, Suh C, Lin T, Kim WS (2017) Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease. Ann Oncol 28:2199–2205CrossRefPubMed
8.
Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS (2009) Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol 27:6027–6032CrossRefPubMed
9.
Michot JM, Mazeron R, Danu A, Lazarovici J, Ghez D, Antosikova A, Willekens C, Chamseddine AN, Minard V, Dartigues P, Bosq J, Carde P, Koscielny S, De Botton S, Ferme C, Girinsky T, Ribrag V (2015) Concurrent etoposide, steroid, high-dose Ara-C and platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. Eur J Cancer 51:2386–2395CrossRefPubMed
10.
Okamoto M, Maruyama F, Tsuzuki M, Nomura T, Miyazaki H, Wakita M, Kojima H, Sobue R, Matsui T, Ino T (1994) Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin’s lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin. Rinsho Ketsueki 35:635–641PubMed
Metadata
Title
Successful full-dose DeVIC therapy in a patient with advanced-stage extranodal natural killer/T-cell lymphoma refractory to l-asparaginase
Authors
Junko Watanabe
Shinichi Makita
Yuta Ito
Shunsuke Hatta
Tomotaka Suzuki
Sayako Yuda
Akiko Miyagi Maeshima
Suguru Fukuhara
Wataru Munakata
Tatsuya Suzuki
Dai Maruyama
Sung-Won Kim
Koji Izutsu
Publication date
01-09-2018
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 9/2018
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-018-3335-4

Other articles of this Issue 9/2018

Annals of Hematology 9/2018 Go to the issue

Letter to the Editor

Copper deficiency: a cause of misdiagnosis of myelodysplastic syndrome

Original Article

The WHO diagnostic criteria for polycythemia vera—role of red cell mass versus hemoglobin/hematocrit level and morphology

Original Article

Allogeneic stem cell transplantation recipients requiring intensive care: time is of the essence

Original Article

Incidence, predictive factors, management, and survival impact of atrial fibrillation in non-Hodgkin lymphoma

Original Article

Efficacy of decitabine as hemoglobin F inducer in HbE/β-thalassemia

Original Article

A higher percentage of cells with 13q deletion predicts worse outcome in Chinese patients with chronic lymphocytic leukemia carrying isolated 13q deletion
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits